Clinical outcomes associated with brand-to-generic phenytoin interchange;Resultados Clínicos Relacionados con el Intercambio de la Fenitoína de Marca a la Genérica

Annals of Pharmacotherapy

Volumn 46, Issue 5, 2012, Pages 650-658

  Kinikar, Shilpa A ^a,b   Delate, Thomas ^c   Mindy Menaker Wiener, C ^d   Bentley, William H ^d  

^a Departments of Psychiatry Neurology and Physical Medicine and Rehabilitation School of Medicine   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Pharmacy Department   (United States)

^d Departments of Internal Medicine and Metabolic Surgical Weight Management   (United States)

Author keywords

Generic substitution; Phenytoin; Seizures

Indexed keywords

GENERIC DRUG; PHENYTOIN;

ADULT; CONTROLLED STUDY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; SEIZURE; TREATMENT OUTCOME;

ANTICONVULSANTS; DELAYED-ACTION PREPARATIONS; DRUGS, GENERIC; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; RETROSPECTIVE STUDIES; SEIZURES; THERAPEUTIC EQUIVALENCY;

EID: 84860996543     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q601     Document Type: Review

References (23)

1. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249-1250.
2. Position statement on the substitution of different formulations of antiepileptic drugs for the treatment of epilepsy. American Epilepsy Society press release. Hartford, CT, November 29, 2007.
3. Pfizer medication information. Dilantin (phenytoin sodium) 100-mg extended oral capsules. http://www.pharmalot.com/wp-content/uploads/2008/05/dilantin-letter.jpg (accessed 2012 Feb 8).
4. Package insert. Dilantin Kapseals (phenytoin) 100 mg. New York, NY: Pfizer, Inc., September 2006. www.pfizer.com/files/products/uspi_di-lantin_kapseals.pdf (accessed 2011 Aug 31).
5. Package insert. Dilantin (phenytoin) 100-mg extended oral capsules. New York, NY: Pfizer Inc., April 2009. http://labeling.pfizer.com/ShowLabeling.aspx?id=545 (accessed 2009 Aug 31).
6. Package insert. Extended phenytoin sodium capsules USP, 100 mg. Hawthorne, NY: Taro Pharmaceuticals USA, Inc., May 2006. www.taro.com/media/oMedia/Extended%20Phenytoin%20Sodium%20Capsules%20USP,100%20mg-PI.pdf (accessed 2011 Aug 31).
7. Kee VR, Gilchrist B, Granner MA, Sarrazin NR, Carnahan RM. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: seizure, convulsion, epilepsy report. http://mini-sentinel.org/work_products/HealthOutcomes/Mini-Sentinel-HOI-Evidence-Review-Seizure-Convulsion-Epilepsy-Report.pdf (accessed 2011 Aug 10).
8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
9. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004;63:1494-1496.
10. Hodges S, Forsythe WI, Gilles D, Remington H, Cawood A. Bio-availability and dissolution of three phenytoin preparations for children. Dev Med Child Neurol 1986;28:708-712.
11. Johannessen SI, Tomson T. General principles laboratory monitoring of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. Philadelphia: Lippincott Williams & Wilkins, 2002.
12. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-1276.
13. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: re-examining its role in the treatment of epilepsy. Epilepsia 2000;41:S6-S15. DOI 10.1111/j.1528-1157.2000.tb02950.x
14. Camfield P, Camfield C. Monitoring for adverse effects of antiepileptic drugs. Epilepsia 2006;47:31-34. DOI 10.1111/j.1528-1167.2006.00657.x
15. Kishore K, Jailakhani BL, Sharma JN, Ahuja GK. Serum phenytoin levels with different brands. Indian J Physiol Pharmacol 1986;30:171-176.
16. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55:688-691.
17. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following use of generic vs brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;70:605-621.
18. Zachry WM III, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009;50:493-500. DOI 10.1111/j.1528-1167.2008.01703.x
19. Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009;29:764-779. DOI 10.1592/phco.29.7.769
20. Hansen RN, Campbell JD, Sullivan SD. Association between antiepilep-tic drug switching and epilepsy-related events. Epilepsy Behav 2009;15: 481-485. DOI 10.1016/j.yebeh.2009.05.019
21. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther 2010;88:347-353. DOI 10.1038/clpt.2010.90
22. Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol 2007;64:1595-1599.
23. Ettinger AB, Adigha RK. Breakthrough seizures-approach to prevention and diagnosis. US Neurology 2008;4:40-42.